LASA Supergenerics discloses related party transactions for Q4FY26
LASA Supergenerics Limited disclosed related party transactions for Q4FY26, reporting ₹35.36 lakh in actual transactions against an approved limit of ₹618 lakh. Payments included remuneration for directors and a donation to the Dr Omkar Herlekar Foundation.

*this image is generated using AI for illustrative purposes only.
Lasa Supergenerics Limited has disclosed its related party transactions for the quarter and year ended March 31, 2026. The filing, submitted to the stock exchanges on May 29, 2026, details payments made to directors, key managerial personnel, and a foundation connected to the company. The total value of transactions executed during the reporting period amounted to ₹35.36 lakh, against an approved limit of ₹618 lakh by the audit committee.
The disclosures were made in compliance with Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The transactions primarily cover remuneration, sitting fees, and donations. The company’s Chairman and Managing Director, Omkar Herlekar, received ₹3 lakh, while Whole Time Directors Umesh Pawar, Prathmesh Chalke, and Ganesh Potdar received ₹1.49 lakh, ₹4.63 lakh, and ₹0.30 lakh respectively.
Breakdown of Transactions
The following table summarizes the key related party transactions reported for the period:
| Related Party | Relationship | Transaction Type | Approved Value (₹ lakh) | Reporting Period Value (₹ lakh) |
|---|---|---|---|---|
| Mr. Omkar Herlekar | Promoter-Managing Director | Directors Remuneration | 100 | 3.00 |
| Mr. Umesh Pawar | Whole Time Director | Directors Remuneration | 100 | 1.49 |
| Mrs Mitti Jain | Company Secretary | Remuneration | 100 | 5.59 |
| Dr Omkar Herlekar Foundation | Common Director | Donation Given | 200 | 15.50 |
| Mr. Prathmesh Chalke | Whole Time Director | Directors Remuneration | 8 | 4.63 |
Independent Directors received sitting fees for their participation in board meetings. Ms. Ekta Gurnasinghani, Mr. Hardesh Tolani, and Ms. Manali Bhagtani each received ₹0.75 lakh. Other independent directors, including Ms. Ajay Sukhwani, Mr. Yogesh Hari Ughada, Mr. Pravin Gadalya Lachake, Mr. Ketan Bhau Songal, and Ms. Rekha Hemant Wakh, received amounts ranging from ₹0.10 lakh to ₹1.00 lakh.
The Chief Financial Officers (CFOs), Mr. Ravi Shankar Kabra and Ms. Varsha Joshi, were remunerated ₹0 and ₹1.20 lakh respectively during the quarter. The audit committee had previously approved a total remuneration limit of ₹30 lakh for Mr. Kabra and ₹8 lakh for Ms. Joshi.
Historical Stock Returns for Lasa Supergenerics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.84% | +1.71% | +2.72% | -12.80% | -47.96% | -89.34% |
How will the company's related party transaction strategy evolve as it approaches the next fiscal year?
What impact might the significant donation to the Dr Omkar Herlekar Foundation have on future corporate social responsibility initiatives?
Could the disparity in remuneration limits versus actual payouts signal a shift in executive compensation policies?


































